Stock
16 years ago
Historical Prices
Date Open High Low Close Volume AdjClose
2006/10/04 - - - - - -
2006/10/03 0.90 0.90 0.85 0.87 84,703 0.87
2006/10/02 0.89 0.92 0.88 0.90 76,326 0.90
2006/09/29 0.85 0.93 0.85 0.90 244,439 0.90
2006/09/28 0.88 0.91 0.85 0.90 53,218 0.90
2006/09/27 0.88 0.88 0.85 0.86 39,200 0.86
2006/09/26 0.87 0.92 0.85 0.88 45,769 0.88
2006/09/25 0.90 0.95 0.85 0.88 115,909 0.88
2006/09/22 0.93 0.93 0.89 0.92 58,564 0.92
2006/09/21 0.87 0.93 0.83 0.90 89,654 0.90
2006/09/20 0.97 0.97 0.90 0.90 52,618 0.90
2006/09/19 0.97 0.98 0.90 0.94 91,226 0.94
2006/09/18 0.98 0.99 0.97 0.99 31,755 0.99
2006/09/15 0.96 0.99 0.96 0.99 89,250 0.99
2006/09/14 0.98 0.98 0.96 0.98 144,757 0.98
2006/09/13 0.95 0.99 0.93 0.98 166,244 0.98
2006/09/12 0.97 1.01 0.95 1.00 406,761 1.00
2006/09/11 0.98 1.03 0.98 1.00 151,475 1.00
2006/09/08 0.97 1.01 0.97 1.01 47,752 1.01
2006/09/07 1.01 1.03 1.00 1.00 69,650 1.00
2006/09/06 0.95 1.04 0.95 1.00 190,034 1.00
2006/09/05 1.00 1.05 0.95 1.00 111,858 1.00
2006/09/04 1.00 1.02 1.00 1.02 73,439 1.02
2006/09/01 1.00 1.06 1.00 1.02 70,139 1.02
2006/09/01 1.00 1.06 1.00 1.02 73,439 1.02
2006/08/31 1.04 1.14 1.00 1.05 144,934 1.05
2006/08/30 0.96 9,600.00 0.91 1.01 239,129 1.01 << db error
2006/08/29 0.85 0.95 0.85 0.95 156,342 0.95
2006/08/28 0.85 0.88 0.85 0.86 237,605 0.86
2006/08/25 0.86 0.90 0.83 0.87 43,530 0.87
2006/08/24 0.86 0.88 0.85 0.86 19,009 0.86
2006/08/23 0.87 0.90 0.85 0.86 68,195 0.86
2006/08/22 0.86 0.89 0.85 0.87 87,778 0.87
2006/08/21 0.85 0.88 0.85 0.86 48,800 0.86
2006/08/18 0.86 0.87 0.84 0.85 161,977 0.85
2006/08/17 0.85 0.87 0.85 0.86 73,806 0.86
2006/08/16 0.86 0.87 0.85 0.85 143,763 0.85
2006/08/15 0.85 0.87 0.85 0.86 145,345 0.86
2006/08/14 0.85 0.86 0.85 0.85 87,077 0.85
2006/08/11 0.86 0.86 0.85 0.85 54,930 0.85
2006/08/10 0.85 0.87 0.85 0.86 14,708 0.86
2006/08/09 0.85 0.86 0.85 0.85 79,850 0.85
2006/08/08 0.85 0.87 0.85 0.85 98,711 0.85
2006/08/07 0.88 0.88 0.85 0.85 150,810 0.85
2006/08/04 0.88 0.89 0.86 0.88 31,210 0.88
2006/08/03 0.89 0.89 0.86 0.88 41,897 0.88
2006/08/01 0.86 0.88 0.85 0.86 74,907 0.86
2006/07/31 0.85 0.89 0.85 0.86 44,916 0.86
2006/07/28 0.85 0.88 0.85 0.85 131,560 0.85
2006/07/27 0.86 0.86 0.85 0.85 35,988 0.85
2006/07/26 0.89 0.89 0.85 0.86 39,270 0.86
2006/07/25 0.88 0.90 0.85 0.89 43,996 0.89
2006/07/24 0.85 0.88 0.85 0.88 53,067 0.88
2006/07/21 0.86 0.88 0.85 0.85 141,419 0.85
2006/07/20 0.87 0.88 0.85 0.86 72,938 0.86
2006/07/19 0.85 0.87 0.85 0.87 59,277 0.87
2006/07/18 0.85 0.87 0.83 0.85 210,868 0.85
2006/07/17 0.85 0.87 0.85 0.85 43,316 0.85
2006/07/14 0.85 0.87 0.85 0.85 77,704 0.85
2006/07/13 0.85 0.88 0.85 0.85 71,659 0.85
2006/07/12 0.85 0.89 0.85 0.85 55,477 0.85
2006/07/10 0.87 0.88 0.85 0.85 73,292 0.85
2006/07/07 0.87 0.87 0.85 0.87 64,990 0.87
2006/07/06 0.86 0.90 0.86 0.87 100,411 0.87
2006/07/05 0.86 0.89 0.85 0.86 214,790 0.86
2006/07/04 0.88 0.88 0.86 0.86 40,490 0.86
2006/07/03 0.85 0.88 0.85 0.86 40,490 0.86
2006/06/30 0.89 0.90 0.85 0.85 68,392 0.85
2006/06/28 0.88 0.89 0.83 0.86 233,451 0.86
2006/06/27 0.91 0.93 0.88 0.88 80,927 0.88
2006/06/26 0.94 0.94 0.91 0.91 96,200 0.91
2006/06/23 0.98 0.98 0.91 0.94 66,135 0.94
2006/06/22 0.99 0.99 0.95 0.98 51,002 0.98
2006/06/21 0.98 1.03 0.97 0.99 51,350 0.99
2006/06/20 1.03 1.04 0.98 0.98 42,694 0.98
2006/06/19 1.00 1.04 0.99 1.03 52,090 1.03
2006/06/16 0.96 1.04 0.96 1.00 147,840 1.00
2006/06/15 0.95 0.97 0.94 0.96 103,131 0.96
2006/06/14 0.95 0.97 0.92 0.95 214,908 0.95
2006/06/13 0.97 0.98 0.91 0.95 94,601 0.95
2006/06/12 0.96 1.00 0.92 0.97 229,840 0.97
2006/06/09 0.94 0.98 0.86 0.96 996,783 0.96
2006/06/08 0.95 0.99 0.80 0.94 1,332,027 0.94
2006/06/07 0.95 0.97 0.92 0.95 67,349 0.95
2006/06/06 0.94 0.97 0.92 0.95 207,747 0.95
2006/06/05 0.96 0.96 0.93 0.94 114,214 0.94
2006/06/02 0.95 0.98 0.93 0.96 112,835 0.96
2006/06/01 0.93 0.94 0.92 0.94 234,160 0.94
2006/05/31 0.93 0.95 0.92 0.93 236,796 0.93
2006/05/30 0.96 0.96 0.92 0.93 70,586 0.93
2006/05/29 0.99 0.99 0.96 0.96 82,687 0.96
2006/05/26 0.97 1.00 0.95 0.96 82,687 0.96
2006/05/25 0.94 0.98 0.92 0.97 122,815 0.97
2006/05/24 0.96 0.96 0.93 0.94 158,166 0.94
2006/05/23 0.96 0.97 0.95 0.96 237,383 0.96
2006/05/22 0.98 0.98 0.94 0.96 238,143 0.96
2006/05/19 1.02 1.03 0.98 0.98 496,916 0.98
2006/05/18 1.01 1.05 1.00 1.02 299,794 1.02
2006/05/17 1.03 1.07 1.01 1.01 300,141 1.01
2006/05/16 1.04 1.07 1.01 1.03 162,497 1.03
Stock
16 years ago
On June 8, 2006, Axonyx Inc. (Nasdaq: AXYX) and privately held
TorreyPines Therapeutics, Inc. announced that they have entered
into a definitive merger agreement. The resulting company
will be named TorreyPines Therapeutics, headquartered in San
Diego, California and traded on the NASDAQ Stock Market
under the proposed ticker symbol “TPTX.”
Terms
• Tax-free stock for stock merger
• Pro forma ownership of combined company
- Approximately 58% TorreyPines shareholders
- Approximately 42% Axonyx shareholders
- In addition, TorreyPines preferred shareholders receive
warrants to purchase combined company shares that, if
fully exercised at closing, give TorreyPines shareholders
approximately 62% of the combined company
- Relative percentages adjusted if either party out-licenses
one or more product candidates prior to closing
• Subject to customary and other closing conditions including
shareholder approval
• Transaction expected to close during the fourth quarter
of 2006
• Board of Directors to consist of five current TorreyPines
directors and three current Axonyx directors
ADVANTAGES OF THE AXONYX AND
TORREYPINES COMBINATION
• Robust and more diversified CNS pipeline to lower
development risk
• Combined company will have eight product candidates
- Novel parenteral and oral product candidates for pain
- Exceptional portfolio of six Alzheimer’s disease (AD)
product candidates
- Four of eight product candidates in the clinic
• Sufficient cash to advance multiple product candidates to
value-creating milestones
• Well capitalized – the pro forma combined company had
more than $80 million in cash at March 31, 2006
• Drug discovery capability to fuel ongoing product
development
• Established infrastructure and experienced leadership that
has a track record in bringing pharmaceuticals to market
UPCOMING MILESTONES
During the next 12 months, TorreyPines and Axonyx anticipate
several key milestones related to their product candidates.
Among these include the following:
• TorreyPines’ lead compound, tezampanel, is expected to
enter a Phase IIb clinical trial for the treatment of migraine
• TorreyPines expects to file an Investigational New Drug (IND)
application and then begin a Phase I trial for NGX426, the
oral prodrug of tezampanel and the company’s follow-on
compound for migraine and chronic pain
• Axonyx will complete its ongoing Phase I trials with
Posiphen™ for the treatment of AD progression
• Data will become available from TorreyPines’ Phase I
single dose study evaluating NGX267, the company’s
lead muscarinic agonist, in healthy elderly volunteers – a
population reflecting the age of the primary AD population
• TorreyPines plans to initiate a multiple dose Phase I safety
study with NGX267
• Axonyx to begin a Phase I clinical trial with BNC, its highly
selective butyrylcholinesterase inhibitor for the treatment of
severe AD
MANAGEMENT
Dr. Neil Kurtz, President and Chief Executive Officer
Dr. Kurtz is an accomplished clinician with more than 25 years
of global executive management experience in pharmaceutical
and healthcare provider companies. Prior to joining TorreyPines
Therapeutics, Dr. Kurtz co-founded Worldwide Clinical Trials, a contract
research organization, where he held the positions of President and
Chief Executive Officer until its acquisition by UnitedHealth Group
(UHG) in September 1999. After the acquisition, Dr. Kurtz became
President of Ingenix Pharmaceutical Services, a division of UHG, and
also served as a member of the UHG Executive Board until joining
TorreyPines Therapeutics. Dr. Kurtz’s career includes senior positions
with Boots Pharmaceuticals, Bayer Corporation, Bristol-Myers Squibb
Company, and Merck. Over the course of his career, Dr. Kurtz played
instrumental roles in numerous New Drug Applications (NDA)
submissions and successfully brought multiple pharmaceuticals to
market, including the anti-obesity drug Meridia®; Pepcid® for pain
related to stomach ulcers; and the anti-anxiety therapy BuSpar®.
Evelyn Graham, Chief Operating Officer
Prior to joining TorreyPines Therapeutics, Ms. Graham was Executive
Director, Development Operations at Purdue Pharma. In this capacity,
she managed global operations supporting a portfolio of marketed
and early to late-stage pain compounds. Ms. Graham has 19 years
clinical development experience and a proven track record of
establishing and running development operations for pharmaceutical
and contract research organizations. Ms. Graham was Senior Vice
President of Business Development at Ingenix Pharmaceutical
Services, a division of UnitedHealth Group (UHG), and Vice President of
Clinical Operations at Worldwide Clinical Trials, prior to its acquisition
by UHG. Her pharmaceutical experience includes positions in
operations management, healthcare utilization, and organizational
planning at Bayer Corporation and Wyeth Pharmaceuticals (formerly
Ayerst Laboratories).
Craig Johnson, Chief Financial Officer
Mr. Johnson has served as a senior financial executive in the biotech industry
for more than 10 years. Prior to joining TorreyPines Therapeutics, he was
Chief Financial Officer and Senior Vice President of Operations at MitoKor and
previously held financial management positions at several early-stage technology
companies. A Certified Public Account, Mr. Johnson began his career working for
the accounting firm Price Waterhouse LLP.
Dr. Michael Murphy, Chief Medical Officer
Prior to joining TorreyPines Therapeutics in 2004, Dr. Murphy was Chief
Medical and Scientific Officer for Ingenix Pharmaceutical Services, a division of
UnitedHealth Group (UHG), and he also served as liaison with other UHG business
units in matters of clinical trial design, regulatory activities and other programs of
research. Prior to its acquisition by UHG, Dr. Murphy was Vice President of Scientific
Affairs at Worldwide Clinical Trials. Previously, he served as Senior Vice President,
Worldwide Clinical Research at Cephalon, Inc., and Vice President, Scientific and
Professional Affairs, Neuroscience-Strategic Business Unit, at Hoechst-Roussel
Pharmaceuticals.
Dr. Steven Wagner, Chief Scientific Officer
Dr. Wagner co-founded TorreyPines Therapeutics, then named Neurogenetics,
in 2000 as its Chief Scientific Officer. Prior, Dr. Wagner was the Director of Protein
Biochemistry at SIBIA Neurosciences. He served as the program head of SIBIA’s
Alzheimer’s disease drug discovery collaboration with Bristol-Myers Squibb (BMS).
This collaboration resulted in the first gamma-secretase inhibitor for Alzheimer’s
disease to reach the clinic. Dr. Wagner was a member of SIBIA’s Strategic Planning
and Drug Discovery Steering Committees and a member of the Joint Steering
Committee between SIBIA and BMS. Dr. Wagner is an inventor on numerous
patents and patent applications and has published over 50 chapters and
research papers in the top scientific journals. Prior to leading SIBIA’s Alzheimer’s
disease drug discovery efforts, Dr. Wagner was a Research Associate Professor
in the Department of Microbiology and Molecular Genetics at the University of
California at Irvine where he co-authored the initial purification and identification
of the human amyloid precursor protein.
http://www.torreypinestherapeutics.com/images/uploads/TPTX-AXYX%20Fact%20Sheet_%20Final.pdf
Golden Cross
19 years ago
Axonyx Announces Completion of the Multiple-Dose Phase I Study of Posiphen(TM)
Monday May 15, 4:15 pm ET
NEW YORK--(BUSINESS WIRE)--May 15, 2006--Axonyx Inc. (NASDAQ: AXYX - News) announced today the completion of its second Phase I study with Posiphen(TM) in clinical development for the treatment of Alzheimer's disease progression.
ADVERTISEMENT
This double-blind, placebo-controlled multiple ascending-dose safety and pharmacokinetic study of Posiphen in healthy volunteers sought to establish well tolerated doses. The initial review of the clinical adverse event data appears to be generally consistent with the results of the earlier single ascending dose Phase I study that suggested that the mean Posiphen blood levels associated with well tolerated doses in humans are higher than those associated with potentially beneficial effects on beta-amyloid metabolism in animal models. The build-up of beta-amyloid (Aa) is generally believed to be causative of the dementia of Alzheimer's disease and its progression. No serious adverse events were reported at any dose level in this second Phase I study.
This multiple ascending-dose study examined the effects of Posiphen 20, 40 and 60mg given four times daily, for a period of 7, 7 and 10 days respectively. On the first and last day of each dosing period one single dose of Posiphen was given. Each dose period was completed and evaluated for safety and tolerance before the next higher dose level was initiated. Each cohort was composed of a different set of 16 subjects, comprised of 12 who received Posiphen and 4 who received placebo, with equal numbers of males and females in each.
The necessary detailed safety, pharmacokinetic and pharmacodynamic analyses are ongoing. Based on this favourable clinical outcome, Axonyx is evaluating plans regarding the further clinical development steps for Posiphen.
Posiphen(TM)
Current treatment of Alzheimer's disease focuses primarily on acetylcholinesterase inhibition. A major pathological hallmark of AD is the appearance of senile plaques that are primarily composed of aggregated forms of beta-amyloid (A beta) derived from beta-APP. Posiphen appears to modify the metabolism of beta-amyloid precursor protein (beta-APP). Soluble forms of A beta have been shown to cause significant toxicity in vitro and in vivo and hence represent a target for drug development in AD treatment.
The acetylcholinesterase (AChE) inhibitor Phenserine, which is currently in development by the Company mainly for the symptomatic treatment of mild to moderate AD, and its positive isomer, Posiphen, have both been found to significantly reduce beta-APP and A beta in cell culture systems and animals. As a consequence of its apparent lack of AChE inhibitory activity, Posiphen may be administered in relatively high doses. Such high doses may result in potentially meaningful reductions in A beta in Alzheimer's disease patients.
About Axonyx
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds for the treatment of Central Nervous System disorders. The Company currently has three compounds in development for Alzheimer's disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer's disease (AD), Posiphen(TM) - a potential disease progression treatment for AD now in Phase I, and BisNorCymserine (BNC) - a potential symptomatic treatment of severe AD now in pre-Investigational New Drug (IND) stage.